Metformin Versus Orlistat in Obese Polycystic Ovary Syndrome (PCOS) Patients

Orlistat Administration Facilitates the Obesity Treatment Among Obese PCOS Women

The purpose of this study is to compare the influence of Orlistat and Metformin on obesity treatment in obese PCOS women.

In a randomized clinical trial study, 80 obese women with BMI≥30, oligomenorrhae, hirsutism and presence of > 12 ovarian follicles (2-10mm diameter), were evaluated. In metformin group , metformin was administered for patients 1500 mg daily for three months. In orlistate group, patients used orlistat tablets (120 mg, 3 times a day) for three months. BMI, serum LH and FSH levels, serum triglyceride and cholesterol levels and also patients' ovulation was compared before and after treatment.

Inclusion Criteria:

• BMI>= 30
• PCOS

Exclusion Criteria:

• Drug use during last three months